Recently added Catalysts

CGTX Positive Sentiment

Episode 8: Protecting the Synapse from Amyloid Toxicity in Alzheimer’s Disease

Monday, May 20, 2024 BiopharmaWatch Research 1 min read

Key Takeaway: The episode features a discussion on protecting synapses from amyloid toxicity in Alzheimer's disease. Moderated by experts from Cognition Therapeutics, it highlights findings from the SEQUEL study and clinical observations related to the drug CT1812. The ongoing Phase 2 study of CT1812 is also discussed, showcasing its potential in Alzheimer's treatment.

Price reaction · baseline $2.01 (2024-05-20T14:36:00.000Z) · hit during market hours · 1 other CGTX headline(s) in the window, move may be shared

day 0 close · peak

+4.5%

Market Sentiment Analysis

POSITIVE FACTORS

Discussion on innovative approaches to Alzheimer's treatment.
Insights from leading experts in the field.
Focus on promising findings from ongoing research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Best trade, last catalyst

+35%

120-day peak, hindsight

Typical move

8.3%

average across 6 past catalysts

Cash runway

~33 mo

Minimal dilution risk

Lead asset

Oxytocin

Phase 2 · Oxidative Stress

Full Press Release Details

Episode 8: Protecting the Synapse from Amyloid Toxicity in Alzheimer’s Disease

Featuring:

Anthony Caggiano, M.D., Ph.D.

(moderator)

Cognition Therapeutics

Chief Medical Officer

Mary Hamby, Ph.D.

(moderator)

Cognition Therapeutics

Vice President of Research

Everard (Jort) Vijverberg, MD, PhD

Alzheimer Center at Amsterdam University Medical Center

Neurologist and CNS Trial Specialist

Tara Spires Jones, DPhil

University of Edinburgh

Personal Chair of Neurodegeneration and Deputy Director of the Centre for Discovery Brain Sciences

Index: